UnknownNot Applicable

Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer

Belgium41 participantsStarted 2022-11-01

Plain-language summary

This clinical prospective randomised controlled trial will evaluate the impact of an ovarian biopsy on the oocyte yield after controlled ovarian stimulation before chemotherapy in view of breast cancer. The purpose of this trial is to learn about the possibility to combine these two fertility preservation procedures without decreasing the number of oocytes collected after an ovarian stimulation.

Who can participate

Age range

18 Years – 35 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 and ≤ 35 years * BMI ≥ 18 and ≤ 35 kg/m² * Diagnosis of breast cancer * Presence of 2 ovaries * Signed informed consent form * Medically fit for general anesthesia (ASA score 1-3) * Permission of oncology team (with agreement to postpone chemo/radiotherapy for at least 2 weeks) * Random start controlled ovarian stimulation * AFC minimum (ie antral follicles measuring between 2-9 mm): 8 antral follicles Exclusion Criteria: * Age \<18 or \>35 years * BMI \<18 or \>35 kg/m² * Difference in AFC between the ovaries of more than 7 antral follicles * Diagnosis of PCOS * Previous radiotherapy and/or chemotherapy (neo-adjuvant chemotherapy included) * Endometriose rAFS 3-4 * Allergy or reaction to the use of Elonva®, Puregon®, Orgalutran®, Pregnyl® Gonapeptyl®, Decapeptyl® or letrozole in the past

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Mature oocyte yield from biopsied versus non-biopsied ovary

Timeframe: Immediately after the procedure of the transvaginal oocyte retrieval

Trial details

NCT IDNCT04586686

SponsorUniversitair Ziekenhuis Brussel

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-11-30

Contact for this trial

Michel De Vos, MD PhD

(0)24776660 mdv@uzbrussel.be

View on ClinicalTrials.gov More Breast Cancer Female trials